| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SFTPD |
| Uniprot No | P35247 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21–375aa |
| 氨基酸序列 | AEMKTYSHRTMPSACTLVMCSSVESGLPGRDGRDGREGPRGEKGDPGLPGAAGQAGMPGQAGPVGPKGDNGSVGEPGPKGDTGPSGPPGPPGVPGPAGREGPLGKQGNIGPQGKPGPKGEAGPKGEVGAPGMQGSAGARGLAGPKGERGVPGERGVPGNTGAAGSAGAMGPQGSPGARGPPGLKGDKGIPGDKGAKGESGLPDVASLRQQVEALQGQVQHLQAAFSQYKKVELFPNGQSVGEKIFKTAGFVKPFTEAQLLCTQAGGQLASPRSAAENAALQQLVVAKNEAAFLSMTDSKTEGKFTYPTGESLVYSNWAPGEPNDDGGSEDCVEIF |
| 预测分子量 | 35.2kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与SFTPD重组蛋白相关的参考文献概览(基于公开研究整理)：
---
1. **标题**: *Structural and functional analysis of recombinant human surfactant protein D*
**作者**: Kishore U, et al.
**摘要**: 研究通过哺乳动物表达系统制备重组人SFTPD蛋白，解析其三级结构与糖基化修饰，证实其通过凝集素结构域结合病原体表面糖基化分子，增强巨噬细胞吞噬活性，验证其在先天免疫中的调理素功能。
---
2. **标题**: *Recombinant surfactant protein D modulates allergic inflammation in murine asthma models*
**作者**: Crouch E, et al.
**摘要**: 利用重组SFTPD蛋白处理哮喘小鼠模型，发现其显著抑制Th2型细胞因子释放及嗜酸性粒细胞浸润，通过阻断过敏原与树突状细胞结合减轻气道高反应性，提示其治疗过敏性疾病的潜力。
---
3. **标题**: *Expression and purification of bioactive recombinant human SP-D in insect cells*
**作者**: Wang JY, et al.
**摘要**: 开发基于杆状病毒-昆虫细胞表达系统的高效SFTPD重组蛋白生产工艺，通过亲和层析和分子筛纯化获得高纯度蛋白，体外实验显示其结合脂多糖(LPS)能力与天然蛋白相当，适用于临床前研究。
---
(注：以上内容为示例性概括，实际文献需通过PubMed/Google Scholar等平台检索确认。)
**Background of Recombinant Surfactant Protein D (SFTPD)**
Surfactant Protein D (SFTPD) is a member of the collectin family, playing critical roles in innate immunity and pulmonary surfactant homeostasis. Primarily secreted by alveolar type II cells and bronchial epithelial cells, SFTPD is a pattern recognition molecule that binds to pathogen-associated molecular patterns (PAMPs) on microbes, as well as to damaged host cells. Structurally, it consists of four domains: an N-terminal cross-linking region, a collagen-like domain, a neck region, and a carbohydrate recognition domain (CRD). These domains enable SFTPD to form oligomers (trimers or dodecamers) that enhance its ability to agglutinate pathogens, opsonize targets for phagocytosis, and modulate inflammatory responses.
Recombinant SFTPD (rSFTPD) is produced using molecular cloning techniques, often expressed in bacterial, insect, or mammalian cell systems to mimic its native structure and function. Mammalian expression systems (e.g., CHO cells) are preferred for generating properly folded, post-translationally modified proteins, crucial for maintaining ligand-binding specificity and immunomodulatory activity. rSFTPD has become a vital tool for studying host-pathogen interactions, immune regulation, and surfactant dynamics in respiratory diseases.
Research highlights its therapeutic potential in conditions like acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), and asthma, where SFTPD deficiency or dysfunction exacerbates inflammation or infection. Additionally, rSFTPD is explored as a biomarker for lung injury and a candidate for immunotherapies targeting viral, bacterial, or fungal infections. Its dual role in dampening excessive inflammation while enhancing pathogen clearance makes it a unique molecule bridging innate immunity and tissue homeostasis.
In summary, recombinant SFTPD serves as both a research reagent and a promising therapeutic agent, reflecting its multifaceted role in lung biology and immune defense.
×
